Why the study?
Hypertension is a major cause of disability and mortality typically managed by medication and lifestyle changes, while catheter-based renal denervation has emerged as a new therapeutic concept.
Does catheter-based renal denervation improve outcomes in patients with hypertension?
Does catheter-based renal denervation improve outcomes in patients with hypertension?
This review summarizes the latest preclinical and clinical evidence for catheter-based renal denervation as a treatment strategy for hypertension.
May support adjunctive renal denervation in resistant hypertension; leaves open need for confirmatory randomized trials.
Hypertension significantly increases the risk of cardiovascular events and it is associated with high rates of disability and mortality. Hypertension is a common cause of cardiovascular and cerebrovascular accidents, which severely affect patients’ quality of life and lifespan. Current treatment strategies for hypertension are based primarily on medication and lifestyle interventions. The renal sympathetic nervous system plays an important role in the pathogenesis of hypertension, and catheter-based renal denervation (RDN) has provided a new concept for the treatment of hypertension. In recent years, studies on RDN have been performed worldwide. This article reviews the latest preclinical research and clinical evidence for RDN.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: